The role of neural precursor cell-expressed developmentally down-regulated protein 9 in predicting bacillus Calmette-Guerin response in nonmuscle invasive bladder cancer

To report the sensitivity and specificity of neural precursor cell-expressed developmentally down-regulated protein 9 (NEDD9) protein high expression in predicting BCG response and its effect on recurrence or progression free survivals. Between May 2014 and April 2017, a prospective cohort study was...

Full description

Saved in:
Bibliographic Details
Published in:Urologic oncology 2018-05, Vol.36 (5), p.242.e9-242.e14
Main Authors: El-Babouly, Islam M., Desoky, Esam A.E., El Sayed, Diab, Ali, Maged M., Harb, Ola A., Ragab, Ahmed, Sakr, Ahmed M., Fawzi, Amr M., Salama, Nashaat M., Samaha, Ibrahim I.
Format: Article
Language:English
Subjects:
BCG
Bladder cancer
NEDD9
Progression
Recurrence
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To report the sensitivity and specificity of neural precursor cell-expressed developmentally down-regulated protein 9 (NEDD9) protein high expression in predicting BCG response and its effect on recurrence or progression free survivals. Between May 2014 and April 2017, a prospective cohort study was conducted on 105 patients with intermediate or high-risk nonmuscle invasive bladder cancer. Immunohistochemical staining with mouse monoclonal anti-NEDD9 antibody was done. Examination of the slides was done to detect NEDD9 cytoplasmic expression. Intravesical induction bacillus Calmette-Guerin (BCG) instillation therapy was started for all patients 2 to 4 weeks after endoscopy with once weekly instillation for 6 weeks. Intravesical maintenance BCG instillation was then continued every 3 months for at least 1 year. Follow up with cystoscopy every 3 months for 2 years and every 6 months after that. The mean age ± SD of the patients was 57 ± 4.5 years. The median follow-up period was 25 (12–36) months. NEDD9 protein was highly expressed in 61 (58.1%) patients, whereas low expression was in 44 (41.9%) patients. Sensitivity and specificity of NEDD9 high expression in predicting recurrence were 83.6% and 64.2%, respectively. Its sensitivity and specificity in predicting progression to muscle invasion or distant metastases were 91.3% and 51.2%, respectively. Its sensitivity and specificity in predicting complete response to BCG therapy were 84.1% and 80.9%. Kaplan-Meier test showed highly significant difference (P
ISSN:1078-1439
1873-2496
DOI:10.1016/j.urolonc.2018.02.002